Citi continued to remain positive on Zomato Ltd. after it said it will acquire Paytm's ticketing business, but remains bearish on Dr. Lal PathLabs Ltd. Nuvama is optimistic on pharmaceutical sector after strong first quarter earnings.
NDTV Profit tracks what brokerages are putting out on stocks and sectors. Here are all the top calls from analysts you need to know about on Friday.
Citi On Zomato
-
Maintained a 'buy' rating on the stock with the target price raised to Rs 300 per share from Rs 280 apiece, indicating a potential upside of 16%.
-
Acquisition of Paytm ticketing business moderately positive.
-
Zomato to benefit from over one crore users of Paytm's ticketing business.
-
Will focus on gaining segment market share.
-
Zomato has strong track record.
Zomato To Shut Legends Services Less Than Two Months After Relaunching
Citi On Dr. Lal PathLabs
-
Maintained a 'sell' rating on the stock with a target price of Rs 2,700 per share, indicating a potential downside of 18%.
-
Improvement in mix key to drive realisations.
-
Deeper penetration, geographical expansion to drive volume growth.
-
Competition remains high, irrationality has come down.
-
Margins may remain stable.
-
Renewed focus on international markets.
Nuvama On Pharmaceuticals
-
Pharma index is up 11% since May.
-
Pharma index is at 44% premium to Nifty, with an average of 31% premium.
-
Strong performance in the quarter ended June.
-
Strong commentary by Lupin Ltd. and Zydus Lifesciences Ltd. on the back of launches.
-
Forecasts raised for Lupin, Natco Pharma Ltd., Zydus, Glenmark Pharmaceuticals Ltd.; cut for Biocon Ltd.
Stock Market Live: GIFT Nifty Near 24,800; Zomato, Adani Power, Ambuja Cements, Nykaa In Focus. Read more on Markets by NDTV Profit.